Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

Inclusion Criteria:

1. Age 18 or older

2. Confirmed diagnosis of PSC (with a concurrent diagnosis of inflammatory bowel disease)
characterized by a cholestatic liver condition of greater than 6 months duration with
confirmatory cholangiographic findings, as well as an elevation of the serum alkaline
phosphatase of greater than 1.5 times the upper limit of normal.

Exclusion Criteria:

1. Decompensated liver disease

2. Patients who were pregnant or breastfeeding

3. Use of concomitant immune modulators including methotrexate, mycophenolate mofetil,
tacrolimus, cyclosporine, thalidomide, Interleukin-10, or Interleukin-11 within 4
weeks prior to receiving the FMT

4. Patients who are unable to give informed consent

5. Patients who are unable or unwilling to undergo colonoscopy with moderate sedation
(>ASA class II)

6. Patients who have previously undergone FMT Patients who have a confirmed malignancy or
cancer

7. Patients who are immunocompromised

8. Treatment within last 8 weeks with infliximab, adalimumab, certolizumab, natalizumab,
vedolizumab or thalidomide

9. Antibiotic use within 2-months of start date

10. Participation in a clinical trial in the preceding 30 days or simultaneously during
this trial

11. Probiotic use within 30 days of start date

12. Congenital or acquired immunodeficiencies

13. Other comorbidities including:Diabetes mellitus, cancer, systemic lupus, must be able
to tolerate conscious sedation with colonoscopy

14. Chronic kidney disease as defined by a GFR <60mL/min/1.73m2 44

15. History of rheumatic heart disease, endocarditis, or valvular disease due to risk of
bacteremia from colonoscopy

16. Steroid dose >20mg/day